Jak2

Summary

Gene Symbol: Jak2
Description: Janus kinase 2
Alias: Fd17, tyrosine-protein kinase JAK2, JAK-2
Species: mouse
Products:     Jak2

Top Publications

  1. Nefedova Y, Nagaraj S, Rosenbauer A, Muro Cacho C, Sebti S, Gabrilovich D. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65:9525-35 pubmed
    ..shown that hyperactivation of the Janus-activated kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) induced by tumor-derived factors (TDF) is responsible for abnormal dendritic cell differentiation...
  2. Liu K, Gaffen S, Goldsmith M. JAK/STAT signaling by cytokine receptors. Curr Opin Immunol. 1998;10:271-8 pubmed
    ..This signaling pathway influences normal cell survival and growth mechanisms and may contribute to oncogenic transformation. ..
  3. Jiang L, Li Z, Rui L. Leptin stimulates both JAK2-dependent and JAK2-independent signaling pathways. J Biol Chem. 2008;283:28066-73 pubmed publisher
    Leptin controls body weight by activating the long form of the leptin receptor (LEPRb). Janus kinase 2 (JAK2) is associated with LEPRb and autophosphorylates in response to leptin...
  4. Frenzel K, Wallace T, McDoom I, Xiao H, Capecchi M, Bernstein K, et al. A functional Jak2 tyrosine kinase domain is essential for mouse development. Exp Cell Res. 2006;312:2735-44 pubmed
    b>Jak2 is a member of the Janus family of tyrosine kinases and is involved in cytokine signaling...
  5. Lacout C, Pisani D, Tulliez M, Gachelin F, Vainchenker W, Villeval J. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-60 pubmed
    A JAK2(V617F) mutation is frequently found in several BCR/ABL-negative myeloproliferative disorders...
  6. Li J, Spensberger D, Ahn J, Anand S, Beer P, Ghevaert C, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116:1528-38 pubmed publisher
    The JAK2 V617F mutation is found in most patients with a myeloproliferative neoplasm and is sufficient to produce a myeloproliferative phenotype in murine retroviral transplantation or transgenic models...
  7. Qing Y, Costa Pereira A, Watling D, Stark G. Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J Biol Chem. 2005;280:1849-53 pubmed
    ..Mutation of Tyr(441) also blocked the ability of SOCS-1 to bind to IFNGR1 and JAK2 in response to IFNgamma and the normal down-regulation of STAT1 activation and antiviral activity...
  8. Wang K, Wang C, Xiao F, Wang H, Wu Z. JAK2/STAT2/STAT3 are required for myogenic differentiation. J Biol Chem. 2008;283:34029-36 pubmed publisher
    ..Unexpectedly, we found that a related pathway consisting of JAK2, STAT2, and STAT3 is required for early myogenic differentiation...
  9. Parganas E, Wang D, Stravopodis D, Topham D, Marine J, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-95 pubmed
    ..To assess the role of Jak2, we have derived Jak2-deficient mice...

More Information

Publications62

  1. Endo T, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-4 pubmed
    ..have now isolated a new SH2-domain-containing protein, JAB, which is a JAK-binding protein that interacts with the Jak2 tyrosine-kinase JH1 domain. JAB is structurally related to CIS, a cytokine-inducible SH2 protein...
  2. Akada H, Yan D, Zou H, Fiering S, Hutchison R, Mohi M. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115:3589-97 pubmed publisher
    A somatic point mutation (V617F) in the JAK2 tyrosine kinase was found in a majority of patients with polycythemia vera (PV), essential thrombocythemia, and primary myelofibrosis...
  3. Harpur A, Andres A, Ziemiecki A, Aston R, Wilks A. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene. 1992;7:1347-53 pubmed
    ..The anticipated amino acid sequence of JAK2 predicts the presence of two kinase-related domains, a feature characteristic of this family of PTKs...
  4. Fujinaka Y, Takane K, Yamashita H, Vasavada R. Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation. J Biol Chem. 2007;282:30707-17 pubmed
    ..this protective effect is the janus-activated-kinase-2/signal transducer and activator of transcription-5 (JAK2/STAT5) pathway...
  5. Sandberg E, Wallace T, Godeny M, VonDerLinden D, Sayeski P. Jak2 tyrosine kinase: a true jak of all trades?. Cell Biochem Biophys. 2004;41:207-32 pubmed
    Discovered roughly 10 yr ago, Jak2 tyrosine kinase has emerged as a critical molecule in mammalian development, physiology, and disease. Here, we review the early history of Jak2 and its role in health and disease...
  6. Kamishimoto J, Tago K, Kasahara T, Funakoshi Tago M. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation. Cell Signal. 2011;23:849-56 pubmed publisher
    The disruption of Janus kinase 2 (JAK2) signaling regulation by its point mutation, V617F, is involved in various myeloproliferative disorders (MPDs)...
  7. Wagner K, Krempler A, Triplett A, Qi Y, George N, Zhu J, et al. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice. Mol Cell Biol. 2004;24:5510-20 pubmed
    b>Jak2 is a hormone-receptor-coupled kinase that mediates the tyrosine phosphorylation and activation of signal transducers and activators of transcription (Stat)...
  8. Shide K, Shimoda H, Kumano T, Karube K, Kameda T, Takenaka K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008;22:87-95 pubmed
    An acquired JAK2 V617F mutation is found in most patients with polycythemia vera (PV), and about half of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF)...
  9. Funakoshi Tago M, Tago K, Sumi K, Abe M, Aizu Yokota E, Oshio T, et al. The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice. J Biol Chem. 2009;284:12680-90 pubmed publisher
    b>JAK2 plays important roles in the regulation of a variety of cellular processes including cell migration, proliferation, and protection from apoptosis...
  10. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem. 2002;277:47954-63 pubmed
    ..Here, we found that the JH2 domain negatively regulates the activity of Jak2 and Jak3...
  11. Kubovcakova L, Lundberg P, Grisouard J, Hao Shen H, Romanet V, Andraos R, et al. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013;121:1188-99 pubmed publisher
    ..neoplasms (MPNs), we first performed a detailed phenotypic characterization of Cre-inducible transgenic JAK2-V617F mice...
  12. Nicholson S, Willson T, Farley A, Starr R, Zhang J, Baca M, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999;18:375-85 pubmed
    ..Thus, although inhibition of signaling by SOCS-1 and SOCS-3 requires both the SH2 and N-terminal domains, their mechanisms of action appear to be biochemically different. ..
  13. Wernig G, Gonneville J, Crowley B, Rodrigues M, Reddy M, Hudon H, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008;111:3751-9 pubmed publisher
    The V617F activating point mutation in Jak2 is associated with a proportion of myeloproliferative disorders...
  14. Liu P, Caulder E, Li J, Waeltz P, Margulis A, Wynn R, et al. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. Clin Cancer Res. 2009;15:6891-900 pubmed publisher
    ..We tested the efficacy of a selective JAK1/2 inhibitor in cellular and in vivo models of JAK2-driven malignancy. A novel inhibitor of JAK1/2 was characterized using kinase assays...
  15. Plo I, Nakatake M, Malivert L, de Villartay J, Giraudier S, Villeval J, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008;112:1402-12 pubmed publisher
    The JAK2(V617F) mutation is frequently observed in classical myeloproliferative disorders, and disease progression is associated with a biallelic acquisition of the mutation occurring by mitotic recombination...
  16. Libani I, Guy E, Melchiori L, Schiro R, Ramos P, Breda L, et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood. 2008;112:875-85 pubmed publisher
    ..Thalassemic cells were associated with expression of cell cycle-promoting genes such as EpoR, Jak2, Cyclin-A, Cdk2, and Ki-67 and the antiapoptotic protein Bcl-X(L)...
  17. Wilks A. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86:1603-7 pubmed
    ..The PCR library was then screened by DNA sequencing for PTK-related sequences. Two sequences were identified that, on the basis of sequence comparison with known PTKs, may encode representatives of a new class of PTK. ..
  18. Mullally A, Lane S, Ball B, Megerdichian C, Okabe R, Al Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584-96 pubmed publisher
    ..Treatment with a JAK2 kinase inhibitor ameliorated the MPN phenotype, but did not eliminate the disease-initiating population...
  19. Sos B, Harris C, Nordstrom S, Tran J, Balazs M, Caplazi P, et al. Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest. 2011;121:1412-23 pubmed publisher
    ..Because GH signals through JAK2, we developed mice bearing hepatocyte-specific deletion of JAK2 (referred to herein as JAK2L mice)...
  20. Witthuhn B, Quelle F, Silvennoinen O, Yi T, Tang B, Miura O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993;74:227-36 pubmed
    ..Here we demonstrate that EPO induces tyrosine phosphorylation of JAK2 kinase and activates its in vitro autophosphorylation...
  21. Funakoshi Tago M, Tago K, Abe M, Sonoda Y, Kasahara T. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem. 2010;285:5296-307 pubmed publisher
    It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be ..
  22. Sakamoto K, Lin W, Triplett A, Wagner K. Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy. Cancer Res. 2009;69:6642-50 pubmed publisher
    The Janus kinase 2 (Jak2) is essential for normal mammary gland development, but this tyrosine kinase and its main effector, signal transducer and activator of transcription 5, are also active in a significant subset of human breast ..
  23. James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-8 pubmed
    ..Here, we describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (> 80%) polycythaemia vera patients...
  24. Kurzer J, Argetsinger L, Zhou Y, Kouadio J, O Shea J, Carter Su C. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol Cell Biol. 2004;24:4557-70 pubmed
    The tyrosine kinase Janus kinase 2 (JAK2) binds to the majority of the known members of the cytokine family of receptors...
  25. Park S, Wamsley H, Bae K, Hu Z, Li X, Choe S, et al. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS ONE. 2013;8:e59675 pubmed publisher
    Germline deletion of Jak2 in mice results in embryonic lethality at E12.5 due to impaired hematopoiesis. However, the role that Jak2 might play in late gestation and postnatal life is unknown...
  26. Wood A, Chen E, Donaldson I, Hattangadi S, Burke K, Dawson M, et al. ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood. 2009;114:1820-30 pubmed publisher
    ..an acquired mutation in the majority of patients with myeloproliferative disorders (MPDs) and the key role of the JAK2-STAT5 signaling cascade in normal hematopoiesis has focused attention on the downstream transcriptional targets of ..
  27. Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN?. Blood. 2013;122:1464-77 pubmed publisher
    The acquired gain-of-function V617F mutation in the Janus Kinase 2 (JAK2(V617F)) is the main mutation involved in BCR/ABL-negative myeloproliferative neoplasms (MPNs), but its effect on hematopoietic stem cells as a driver of disease ..
  28. Mullally A, Poveromo L, Schneider R, Al Shahrour F, Lane S, Ebert B. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood. 2012;120:166-72 pubmed publisher
    ..These findings recapitulate the development of post-PV myelofibrosis in human myeloproliferative neoplasms. In aggregate, these results demonstrate the distinct roles of LT-HSCs and erythroid precursors in the pathogenesis of PV...
  29. Kent D, Li J, Tanna H, Fink J, Kirschner K, Pask D, et al. Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol. 2013;11:e1001576 pubmed publisher
    ..reflect transformation of a hematopoietic stem cell (HSC) and the majority harbor an acquired V617F mutation in the JAK2 tyrosine kinase, making them a paradigm for studying the early stages of tumor establishment and progression...
  30. Funakoshi Tago M, Pelletier S, Moritake H, Parganas E, Ihle J. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol. 2008;28:1792-801 pubmed
    ..In a screen to identify phosphorylation events regulating Jak2 activity in EpoR signaling, we identified a mutant (Jak2-Y613E) which has the property of being constitutively ..
  31. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409 pubmed
    ..A targeted inactivation of Jak2 was performed. Jak2-/- embryos are anemic and die around day 12.5 postcoitum...
  32. Huang L, Constantinescu S, Lodish H. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8:1327-38 pubmed
    We show that Janus kinase 2 (JAK2), and more specifically just its intact N-terminal domain, binds to the erythropoietin receptor (EpoR) in the endoplasmic reticulum and promotes its cell surface expression...
  33. Shillingford J, Miyoshi K, Robinson G, Grimm S, Rosen J, Neubauer H, et al. Jak2 is an essential tyrosine kinase involved in pregnancy-mediated development of mammary secretory epithelium. Mol Endocrinol. 2002;16:563-70 pubmed
    ..Based on tissue culture cell experiments, Jak2 is the tyrosine kinase responsible for the phosphorylation of both the PrlR and Stat5...
  34. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962-7 pubmed
    A recurrent somatic activating mutation in the nonreceptor tyrosine kinase JAK2 (JAK2V617F) occurs in the majority of patients with the myeloproliferative disorders polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid ..
  35. Sakamoto K, Creamer B, Triplett A, Wagner K. The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol Endocrinol. 2007;21:1877-92 pubmed
    Using a conditional knockout approach, we previously demonstrated that the Janus kinase 2 (Jak2) is crucial for prolactin (PRL) signaling and normal mammary gland development...
  36. Ishida Takahashi R, Rosario F, Gong Y, Kopp K, Stancheva Z, Chen X, et al. Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling. Mol Cell Biol. 2006;26:4063-73 pubmed
    ..In order to clarify mechanisms by which Jak2, the cognate LRb-associated Jak kinase, is regulated and mediates downstream signaling, we employed tandem mass ..
  37. Mazurkiewicz Munoz A, Argetsinger L, Kouadio J, Stensballe A, Jensen O, Cline J, et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol Cell Biol. 2006;26:4052-62 pubmed
    The tyrosine kinase JAK2 is a key signaling protein for at least 20 receptors in the cytokine/hematopoietin receptor superfamily and is a component of signaling for multiple receptor tyrosine kinases and several G-protein-coupled ..
  38. Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling M, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116:783-7 pubmed publisher
    The Jak2(V617F) mutation is found in most classical BCR/ABL-negative myeloproliferative neoplasms (MPNs)...
  39. Wernig G, Mercher T, Okabe R, Levine R, Lee B, Gilliland D. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-81 pubmed
    ..the role of this mutation in vivo, we transplanted bone marrow (BM) transduced with a retrovirus expressing either Jak2 wild-type (wt) or Jak2V617F into lethally irradiated syngeneic recipient mice...
  40. Funakoshi Tago M, Pelletier S, Matsuda T, Parganas E, Ihle J. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2. EMBO J. 2006;25:4763-72 pubmed
    The tyrosine kinase, Janus kinase-2 (Jak2), plays a pivotal role in signal transduction through a variety of cytokine receptors, including the receptor for erythropoietin (Epo)...
  41. Krempler A, Qi Y, Triplett A, Zhu J, Rui H, Wagner K. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis. 2004;40:52-7 pubmed
    To study biologically relevant functions of the Janus kinase 2 (Jak2) in multiple cytokine and hormone receptor signal transduction pathways, we generated a conditional knockout (floxed) allele of this gene by placing loxP sites around ..
  42. He K, Wang X, Jiang J, Guan R, Bernstein K, Sayeski P, et al. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol Endocrinol. 2003;17:2211-27 pubmed
    ..depends on functional interaction of the GH receptor (GHR) and the cytoplasmic tyrosine kinase, Janus kinase 2 (JAK2), which possesses a C-terminal kinase domain, a catalytically inactive pseudokinase domain just N-terminal to the ..
  43. Zabolotny J, Bence Hanulec K, Stricker Krongrad A, Haj F, Wang Y, Minokoshi Y, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell. 2002;2:489-95 pubmed
    ..In transfection studies, PTP1B dephosphorylates the leptin receptor-associated kinase, Jak2. PTP1B is expressed in hypothalamic regions harboring leptin-responsive neurons...
  44. Shi S, Martin R, Duncan R, Choi D, Lu S, Schroer S, et al. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem. 2012;287:10277-88 pubmed publisher
    ..Mice with hepatocyte-specific deletion of Janus kinase 2 (L-JAK2 KO mice) develop spontaneous steatosis as early as 2 weeks of age...
  45. Kershaw N, Murphy J, Liau N, Varghese L, Laktyushin A, Whitlock E, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol. 2013;20:469-76 pubmed publisher
    ..We determined the crystal structure of a ternary complex between mouse SOCS3, JAK2 (kinase domain) and a fragment of the interleukin-6 receptor ?-chain...
  46. Grebien F, Kerenyi M, Kovacic B, Kolbe T, Becker V, Dolznig H, et al. Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. Blood. 2008;111:4511-22 pubmed publisher
    ..EpoR, like many other receptors involved in hematopoiesis, acts via the kinase Jak2. Deletion of EpoR or Janus kinase 2 (Jak2) causes embryonic lethality as a result of defective erythropoiesis...
  47. Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, et al. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology. 2014;60:334-48 pubmed publisher
    ..Here, we investigated the role of Janus kinase 2 (JAK2) as a newly described intracellular effector of AT1R in mediating liver fibrosis...
  48. Mascarenhas M, Bacon W, Kapeni C, Fitch S, Kimber G, Cheng S, et al. Analysis of Jak2 signaling reveals resistance of mouse embryonic hematopoietic stem cells to myeloproliferative disease mutation. Blood. 2016;127:2298-309 pubmed publisher
    ..For this, they differentially use the Janus kinase (Jak2) and phosphatidylinositol 3-kinase (Pi3k) signaling pathways, with Jak2 mainly relaying the proproliferation ..
  49. Marty C, Lacout C, Droin N, Le Couedic J, Ribrag V, Solary E, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia. 2013;27:2187-95 pubmed publisher
    Although other mutations may predate the acquisition of the JAK2(V617F) mutation, the latter is sufficient to drive the disease phenotype observed in BCR-ABL-negative myeloproliferative neoplasms (MPNs)...
  50. Jakel H, Weinl C, Hengst L. Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control. Oncogene. 2011;30:3502-12 pubmed publisher
    Janus kinase 2 (JAK2) couples ligand activation of cell surface cytokine receptors to the regulation of cellular functions including cell cycle progression, differentiation and apoptosis...
  51. Lu X, Huang L, Lodish H. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem. 2008;283:5258-66 pubmed
    The majority of the BCR-ABL-negative myeloproliferative disorders express the mutant JAK2, JAK2V617F...
  52. Wilks A, Kurban R, Hovens C, Ralph S. The application of the polymerase chain reaction to cloning members of the protein tyrosine kinase family. Gene. 1989;85:67-74 pubmed
    ..In addition to a number of previously described PTK sequences, a novel mammalian PTK-related sequence was uncovered. ..
  53. Choi H, Chung K, Yang H, Ren L, Sohn S, Kim P, et al. Peroxiredoxin V selectively regulates IL-6 production by modulating the Jak2-Stat5 pathway. Free Radic Biol Med. 2013;65:270-279 pubmed publisher
    ..by inhibiting activation of signal transducer and activator of transcription 5 (Stat5) through interaction with Jak2. Notably, this activity of PrdxV was dependent on its catalytic Cys48 residue, but not its peroxidase activity...